Fairman Jeff
Known title: VP, ResearchCIK: 0001813800
Associated companies
Transaction History
| PCVX | ▼ Sell | Open Market | 10,000 | $400K | 10/26/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 5,000 | $128K | 10/11/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,664 | $124K | 9/6/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 336 | $9K | 9/6/2022 | View on chart |
| PCVX | ▼ Sell | Tax Withholding | 519 | $14K | 9/2/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 5,000 | $129K | 8/5/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 10,000 | $255K | 8/4/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,112 | $105K | 5/20/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 888 | $23K | 5/5/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 5,000 | $128K | 4/5/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 10,000 | $255K | 3/11/2022 | View on chart |
| PCVX | ▲ Buy | Grant | 6,000 | $0 | 3/2/2022 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 4,750 | $9K | 12/27/2021 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,575 | $108K | 12/27/2021 | View on chart |
| PCVX | ▼ Sell | Open Market | 175 | $4K | 12/27/2021 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 4,469 | $8K | 12/20/2021 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,619 | $104K | 12/16/2021 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 4,619 | $8K | 12/16/2021 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 131 | $234 | 12/9/2021 | View on chart |
| PCVX | ▼ Sell | Open Market | 131 | $3K | 12/9/2021 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 4,750 | $9K | 10/26/2021 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,750 | $108K | 10/26/2021 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 4,750 | $9K | 9/27/2021 | View on chart |
| PCVX | ▼ Sell | Open Market | 4,611 | $121K | 9/27/2021 | View on chart |
| PCVX | ▼ Sell | Open Market | 139 | $4K | 9/27/2021 | View on chart |
| PCVX | ▲ Buy | Option Exercise | 4,750 | $9K | 8/26/2021 | View on chart |
| PCVX | ▼ Sell | Open Market | 1,532 | $38K | 8/26/2021 | View on chart |
| PCVX | ▼ Sell | Open Market | 3,218 | $83K | 8/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.